Hanson & Doremus Investment Management’s iShares Biotechnology ETF IBB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $397K | Sell |
2,087
-30
| -1% | -$5.16K | 0.04% | 151 |
|
|
2026
Q1 | $357K | Sell |
2,117
-73
| -3% | -$12.5K | 0.04% | 150 |
|
|
2025
Q4 | $370K | Hold |
2,190
| – | – | 0.04% | 136 |
|
|
2025
Q3 | $316K | Hold |
2,190
| – | – | 0.04% | 154 |
|
|
2025
Q2 | $277K | Sell |
2,190
-291
| -12% | -$35.7K | 0.04% | 169 |
|
|
2025
Q1 | $317K | Sell |
2,481
-165
| -6% | -$22.4K | 0.05% | 151 |
|
|
2024
Q4 | $350K | Sell |
2,646
-135
| -5% | -$19K | 0.05% | 137 |
|
|
2024
Q3 | $405K | Sell |
2,781
-986
| -26% | -$143K | 0.06% | 124 |
|
|
2024
Q2 | $517K | Sell |
3,767
-199
| -5% | -$26.6K | 0.09% | 108 |
|
|
2024
Q1 | $544K | Sell |
3,966
-103
| -3% | -$14.1K | 0.09% | 107 |
|
|
2023
Q4 | $553K | Sell |
4,069
-293
| -7% | -$35.7K | 0.1% | 100 |
|
|
2023
Q3 | $533K | Sell |
4,362
-446
| -9% | -$56.7K | 0.11% | 107 |
|
|
2023
Q2 | $610K | Sell |
4,808
-25
| -0.5% | -$3.25K | 0.13% | 103 |
|
|
2023
Q1 | $624K | Sell |
4,833
-14
| -0.3% | -$1.83K | 0.14% | 98 |
|
|
2022
Q4 | $636K | Sell |
4,847
-1
| -0% | -$129 | 0.14% | 106 |
|
|
2022
Q3 | $567K | Sell |
4,848
-380
| -7% | -$47.2K | 0.15% | 99 |
|
|
2022
Q2 | $615K | Sell |
5,228
-1,440
| -22% | -$171K | 0.15% | 103 |
|
|
2022
Q1 | $869K | Sell |
6,668
-117
| -2% | -$15.2K | 0.19% | 92 |
|
|
2021
Q4 | $1.04M | Buy |
6,785
+128
| +2% | +$19.8K | 0.22% | 81 |
|
|
2021
Q3 | $1.08M | Sell |
6,657
-718
| -10% | -$121K | 0.25% | 82 |
|
|
2021
Q2 | $999K | Buy |
7,375
+442
| +6% | +$68.1K | 0.3% | 67 |
|
|
2021
Q1 | $1.04M | Sell |
6,933
-30
| -0.4% | -$4.76K | 0.24% | 85 |
|
|
2020
Q4 | $1.05M | Sell |
6,963
-412
| -6% | -$58.9K | 0.26% | 77 |
|
|
2020
Q3 | $999K | Sell |
7,375
-404
| -5% | -$54.8K | 0.3% | 67 |
|
|
2020
Q2 | $1.06M | Sell |
7,779
-104
| -1% | -$13.3K | 0.34% | 59 |
|
|
2020
Q1 | $849K | Sell |
7,883
-765
| -9% | -$88.1K | 0.29% | 70 |
|
|
2019
Q4 | $1.04M | Buy |
8,648
+71
| +0.8% | +$7.92K | 0.3% | 73 |
|
|
2019
Q3 | $853K | Sell |
8,577
-1,475
| -15% | -$154K | 0.27% | 81 |
|
|
2019
Q2 | $1.1M | Sell |
10,052
-211
| -2% | -$22.4K | 0.35% | 68 |
|
|
2019
Q1 | $1.15M | Sell |
10,263
-111
| -1% | -$12.2K | 0.38% | 60 |
|
|
2018
Q4 | $1M | Buy |
10,374
+67
| +0.7% | +$7.11K | 0.36% | 61 |
|
|
2018
Q3 | $1.26M | Hold |
10,307
| – | – | 0.39% | 63 |
|
|
2018
Q2 | $1.13M | Buy |
10,307
+81
| +0.8% | +$8.66K | 0.37% | 69 |
|
|
2018
Q1 | $1.09M | Sell |
10,226
-187
| -2% | -$20.7K | 0.34% | 77 |
|
|
2017
Q4 | $1.11M | Sell |
10,413
-195
| -2% | -$20.8K | 0.37% | 71 |
|
|
2017
Q3 | $1.18M | Sell |
10,608
-6
| -0.1% | -$641 | 0.41% | 65 |
|
|
2017
Q2 | $1.1M | Buy |
10,614
+99
| +0.9% | +$9.75K | 0.41% | 70 |
|
|
2017
Q1 | $1.03M | Buy |
10,515
+852
| +9% | +$81.6K | 0.41% | 67 |
|
|
2016
Q4 | $855K | Buy |
9,663
+612
| +7% | +$55.7K | 0.37% | 79 |
|
|
2016
Q3 | $873K | Buy |
9,051
+447
| +5% | +$42.5K | 0.41% | 73 |
|
|
2016
Q2 | $738K | Buy |
8,604
+951
| +12% | +$85.3K | 0.33% | 83 |
|
|
2016
Q1 | $665K | Buy |
7,653
+666
| +10% | +$59.6K | 0.3% | 89 |
|
|
2015
Q4 | $788K | Sell |
6,987
-48
| -0.7% | -$5.21K | 0.36% | 74 |
|
|
2015
Q3 | $711K | Sell |
7,035
-384
| -5% | -$46.1K | 0.34% | 82 |
|
|
2015
Q2 | $912K | Sell |
7,419
-501
| -6% | -$60K | 0.39% | 76 |
|
|
2015
Q1 | $907K | Sell |
7,920
-120
| -1% | -$13.2K | 0.38% | 76 |
|
|
2014
Q4 | $813K | Hold |
8,040
| – | – | 0.35% | 84 |
|
|
2014
Q3 | $733K | Sell |
8,040
-210
| -3% | -$18.4K | 0.33% | 89 |
|
|
2014
Q2 | $707K | Sell |
8,250
-2,607
| -24% | -$205K | 0.33% | 96 |
|
|
2014
Q1 | $856K | Sell |
10,857
-1,803
| -14% | -$150K | 0.4% | 78 |
|
|
2013
Q4 | $958K | Sell |
12,660
-4,800
| -27% | -$341K | 0.46% | 67 |
|
|
2013
Q3 | $1.22M | Sell |
17,460
-1,740
| -9% | -$114K | 0.62% | 51 |
|
|
2013
Q2 | $1.11M | Buy |
+19,200
| New | +$1.11M | 0.61% | 53 |
|
Other funds holding IBB
CB
Hanson & Doremus Investment Management's IBB Position: Q2 2026 in Review
Hanson & Doremus Investment Management reduced its iShares Biotechnology ETF (IBB) stake by 1.4% in Q2 2026, selling an estimated $5.16K and leaving 2,087 shares worth $397K. The position accounts for 0.04% of the portfolio, ranked #151.
Hanson & Doremus Investment Management first reported a position in IBB in Q2 2013 and has held it in 53 quarters since. The position peaked at $1.26M in Q3 2018. 954 funds tracked by Wall St. Rank hold IBB as of Q2 2026.
- Hanson & Doremus Investment Management held 2,087 shares of iShares Biotechnology ETF worth $397K as of Q2 2026.
- Hanson & Doremus Investment Management sold 30 iShares Biotechnology ETF shares in Q2 2026, an estimated $5.16K.
- iShares Biotechnology ETF made up 0.04% of Hanson & Doremus Investment Management's portfolio in Q2 2026, its #151 holding.
- Hanson & Doremus Investment Management first reported a position in iShares Biotechnology ETF in Q2 2013 and has held it in 53 quarters since.
- Hanson & Doremus Investment Management's iShares Biotechnology ETF position peaked at $1.26M in Q3 2018.
- 954 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.
Based on Hanson & Doremus Investment Management's 13F filing for Q2 2026, filed 29 Jul 2026.